Last updated: April 27, 2026
What Is the VRAYLAR Supplier Base and Who Makes the Drug?
VRAYLAR (cariprazine) is manufactured through a multi-party supply chain spanning API (active pharmaceutical ingredient) sourcing, finished-dose production, and packaging and testing. The practical supplier set for VRAYLAR is defined by (1) the NDA/label-described commercial supply chain and (2) the “manufacturer” and “packager” identities disclosed on product labeling and in FDA product listings. Those sources determine which companies are actually on the regulatory record for drug supply.
Which companies are disclosed as manufacturers or packagers for VRAYLAR?
The supplier set is captured in the regulatory product record for the finished dosage form and its packaging sites, which typically appear on the VRAYLAR package label and in FDA’s listing/registry data.
| Supplier role |
What it covers |
Supplier identities |
| Finished-dose manufacturer |
Site(s) that produce the cariprazine capsule product |
Disclosed in FDA product listings and/or package labeling for each strength and dosage form |
| Packager / labeler |
Site(s) that package and label the commercial product |
Disclosed in FDA product listings and/or package labeling for each strength and dosage form |
| Marketing authorization holder / NDA holder |
Entity responsible for the product under the NDA |
Disclosed on label and FDA product record |
| API supplier |
Entity that manufactures cariprazine API |
Commonly disclosed via regulatory submissions and supply chain contracts; direct API vendor identity may not always appear on the package label |
VRAYLAR’s supplier identities are therefore determined at the finished-product level by the manufacturer and packager listed on the commercial label and FDA record, then traced to API supply through regulatory filings and related documentation.
What do VRAYLAR labels typically list for supply chain accountability?
Commercial labels for prescription products generally list the following:
- Manufacturer (the finished-dose manufacturing site and/or the legal manufacturer)
- Packager (the packaging site when it differs)
- Labeler (often the same entity as the marketing authorization holder)
In the VRAYLAR case, these entries are the determinative supplier contacts for procurement and quality oversight because they are the entities accountable for the finished product in the U.S. market.
How should procurement teams map VRAYLAR suppliers to R&D and manufacturing risk?
A supplier map that works for high-stakes sourcing does not stop at “API vs finished dose.” It breaks the workflow into compliance-relevant nodes.
Supply-chain nodes
| Node |
Why it matters |
Primary artifacts to verify |
| API production |
Drives raw-material impurity profile and process robustness |
FDA Chemistry/Manufacturing Controls references in submissions; API CoA scope; site registrations where available |
| Finished-dose manufacturing |
Controls blend uniformity, dissolution, and stability outcomes |
Batch records, manufacturing site qualification status, site GMP history |
| Packaging and labeling |
Controls correct strength, imprinting, packaging integrity, and traceability |
Packaging line qualification; serialization/traceability approach if applicable |
How many supplier sites does VRAYLAR typically use across strengths?
VRAYLAR is marketed in multiple strengths (capsules). In practice, multi-strength products often use either:
- One finished-dose manufacturer with common packaging sites across strengths, or
- Different manufacturing and/or packaging sites by strength to balance capacity
The only supplier count that matters for compliance and continuity planning is the number of distinct manufacturer and packager sites shown on the product label and in the FDA record for each strength.
What is the regulatory basis used to identify VRAYLAR suppliers in the U.S.?
For U.S. sourcing, the determinative references are:
- FDA drug product listing (NDC-level) showing manufacturer and labeler/packager entries
- U.S. prescribing information (label) identifying the marketing authorization holder and sometimes manufacturing responsibilities
- Package labeling printed on the commercial units shipped in-market
These sources define “who” for supplier onboarding, supplier audits, and quality agreement execution.
VRAYLAR supplier shortlist for due diligence (what to ask suppliers to prove)
Even when the regulatory record lists a company, procurement and quality teams should verify that the named entity is the one supplying to the distribution channel and that the site is producing under an approved process.
Minimum proof points
- GMP certificate (or FDA inspection history where applicable) for the specific site producing the finished dosage
- Batch manufacturing record traceability to the commercial lots (at least CoA linkage)
- Packaging line traceability to confirm correct labeling/serialization and lot reconciliation
- Change control documentation for formulation/process changes affecting the cariprazine capsule
Key Takeaways
- VRAYLAR’s supplier base is defined at the finished-dose level by the manufacturer and packager identities shown on the commercial label and FDA product listing records.
- API vendor names may not always appear on the package label; procurement should map API supply through regulatory filings and quality documentation, then align it to finished-dose sites for batch traceability.
- Supplier due diligence should be node-based: API, finished-dose manufacturing, and packaging/labeling each carry distinct quality risks.
FAQs
-
Are VRAYLAR suppliers the same across all capsule strengths?
Not always. Manufacturer and packager can vary by strength based on capacity and validated processes. The supplier list is verified at the NDC and strength level.
-
Does the VRAYLAR package label list the API manufacturer?
Usually no. Labels more commonly list finished-dose manufacturers and packagers. API supplier identities typically come from filings and quality documentation rather than consumer-facing labeling.
-
What document should define the “supplier of record” for VRAYLAR procurement?
The FDA product listing and the on-pack labeling manufacturer/packager entries at the relevant NDC and strength.
-
Can one company be both the labeler and the packager?
Yes. Many products show the same legal entity across labeler and packager roles, but site-level verification still matters.
-
What’s the fastest way to build a compliant VRAYLAR supplier map?
Start with NDC-level FDA listing entries for manufacturer and packager, then connect those to API and packaging quality documentation through batch traceability.
References (APA)
[1] FDA. (n.d.). Drug product labeling and NDC directory materials for VRAYLAR (cariprazine). U.S. Food and Drug Administration.
